Sign in with Google
bullish
Wuxi Biologics Placement - Laying the Groundwork for Future Growth
420 Views02 Feb 2021 11:24
Wuxi Biologics (2269 HK) is looking to raise US$1.3bn in its primary placement to fund acquisitions and expand capacity. This is the company's 13th placement since it listed in June 2017.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Zhen Zhou, Toh
APAC IPOs & Placements
Price Chart(Sign Up to Access)
- Pre-IPO SciClone Pharmaceuticals - Here Are the Strength and the Concerns08 Feb 2021
- China Healthcare Weekly (Feb.5)07 Feb 2021
- Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?03 Feb 2021
- Wuxi Biologics (2269 HK) - A Monopoly in China Macromolecule CDMO20 Jan 2021
- Wuxi Biologics Placement - Well Ahead of Lock-Up, Again04 Jan 2021
- Wuxi Biologics Placement - Another One Before Lock-Up, but Just in Time for the Index Inclusion01 Sep 2020
x